Skip to content

Empagliflozin

Empagliflozin (sold as Jardiance) is an SGLT2 inhibitor for Type 2 Diabetes Mellitus and Heart Failure. This shelf carries one product, Empagliflozin Tablets, in 10 mg and 25 mg strengths.

Empagliflozin Tablets

Type 2 Diabetes Mellitus, Heart Failure

10mg · 25mg

Empagliflozin tablets for type 2 diabetes and heart failure. They lower blood sugar by letting the kidneys remove it in urine.

From$4.68/ tabletView

Key points

  • Empagliflozin is an SGLT2 inhibitor: it stops the kidneys from pulling sugar back into the blood, so glucose leaves the body in urine.
  • Ketoacidosis, dehydration, and genital or urinary infections are important risks the label highlights.

Beyond glucose lowering

The label lists established roles in selected adults with heart failure or chronic kidney disease, beyond glucose lowering. Glyxambi pairs empagliflozin with the DPP-4 inhibitor linagliptin in a single tablet, combining two approaches to Diabetes Management.

Further reading